These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 29770579)

  • 1. Cholinesterase targeting by polyphenols: A therapeutic approach for the treatment of Alzheimer's disease.
    Jabir NR; Khan FR; Tabrez S
    CNS Neurosci Ther; 2018 Sep; 24(9):753-762. PubMed ID: 29770579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tea polyphenols as multi-target therapeutics for Alzheimer's disease: An in silico study.
    Mazumder MK; Choudhury S
    Med Hypotheses; 2019 Apr; 125():94-99. PubMed ID: 30902161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Increasing Role of Polyphenols as Novel Therapeutics for Alzheimer's: A Review.
    Karim N; Khan H; Khan I; Guo O; Sobarzo-Sánchez E; Rastrelli L; Kamal MA
    Med Chem; 2020; 16(8):1007-1021. PubMed ID: 31702507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alzheimer's Disease: A Systemic Review of Substantial Therapeutic Targets and the Leading Multi-functional Molecules.
    Umar T; Hoda N
    Curr Top Med Chem; 2017; 17(31):3370-3389. PubMed ID: 29332579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular Insight into the Therapeutic Promise of Flavonoids against Alzheimer's Disease.
    Uddin MS; Kabir MT; Niaz K; Jeandet P; Clément C; Mathew B; Rauf A; Rengasamy KRR; Sobarzo-Sánchez E; Ashraf GM; Aleya L
    Molecules; 2020 Mar; 25(6):. PubMed ID: 32168835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review on cholinesterase inhibitors for Alzheimer's disease.
    Anand P; Singh B
    Arch Pharm Res; 2013 Apr; 36(4):375-99. PubMed ID: 23435942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural Polyphenols in the Treatment of Alzheimer's Disease.
    Syarifah-Noratiqah SB; Naina-Mohamed I; Zulfarina MS; Qodriyah HMS
    Curr Drug Targets; 2018; 19(8):927-937. PubMed ID: 28356027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An update on drug treatment options of Alzheimer's disease.
    Allgaier M; Allgaier C
    Front Biosci (Landmark Ed); 2014 Jun; 19(8):1345-54. PubMed ID: 24896354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small molecule therapeutics for tauopathy in Alzheimer's disease: Walking on the path of most resistance.
    Wang L; Bharti ; Kumar R; Pavlov PF; Winblad B
    Eur J Med Chem; 2021 Jan; 209():112915. PubMed ID: 33139110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alzheimer's disease (AD) therapeutics - 1: Repeated clinical failures continue to question the amyloid hypothesis of AD and the current understanding of AD causality.
    Mullane K; Williams M
    Biochem Pharmacol; 2018 Dec; 158():359-375. PubMed ID: 30273553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploration of Various Proteins for the Treatment of Alzheimer's Disease.
    Islam BU; Zaidi SK; Kamal MA; Tabrez S
    Curr Drug Metab; 2017; 18(9):808-813. PubMed ID: 28164752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and Emerging Pharmacological Targets for the Treatment of Alzheimer's Disease.
    Morsy A; Trippier PC
    J Alzheimers Dis; 2019; 72(s1):S145-S176. PubMed ID: 31594236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Connecting the Dots: Linking the Biochemical to Morphological Transitions in Alzheimer's Disease.
    Baig AM
    ACS Chem Neurosci; 2019 Jan; 10(1):21-24. PubMed ID: 30160095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Silico Analysis of Green Tea Polyphenols as Inhibitors of AChE and BChE Enzymes in Alzheimer's Disease Treatment.
    Ali B; Jamal QM; Shams S; Al-Wabel NA; Siddiqui MU; Alzohairy MA; Al Karaawi MA; Kesari KK; Mushtaq G; Kamal MA
    CNS Neurol Disord Drug Targets; 2016; 15(5):624-8. PubMed ID: 26996169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical evaluation of current Alzheimer's drug discovery (2018-19) & futuristic Alzheimer drug model approach.
    Dorababu A
    Bioorg Chem; 2019 Dec; 93():103299. PubMed ID: 31586701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroprotective effects of multifaceted hybrid agents targeting MAO, cholinesterase, iron and β-amyloid in ageing and Alzheimer's disease.
    Weinreb O; Amit T; Bar-Am O; Youdim MB
    Br J Pharmacol; 2016 Jul; 173(13):2080-94. PubMed ID: 26332830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic strategies for Alzheimer's disease in clinical trials.
    Godyń J; Jończyk J; Panek D; Malawska B
    Pharmacol Rep; 2016 Feb; 68(1):127-38. PubMed ID: 26721364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Alzheimer disease: cellular and molecular aspects].
    Octave JN
    Bull Mem Acad R Med Belg; 2005; 160(10-12):445-9; discussion 450-1. PubMed ID: 16768248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Features and outcomes of drugs for combination therapy as multi-targets strategy to combat Alzheimer's disease.
    Sahoo AK; Dandapat J; Dash UC; Kanhar S
    J Ethnopharmacol; 2018 Apr; 215():42-73. PubMed ID: 29248451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.